Your browser doesn't support javascript.
loading
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux, Pierre; Giagounidis, Aristoteles; Selleslag, Dominik; Beyne-Rauzy, Odile; Mittelman, Moshe; Muus, Petra; Nimer, Stephen D; Hellström-Lindberg, Eva; Powell, Bayard L; Guerci-Bresler, Agnes; Sekeres, Mikkael A; Deeg, H Joachim; Del Cañizo, Consuelo; Greenberg, Peter L; Shammo, Jamile M; Skikne, Barry; Yu, Xujie; List, Alan F.
Afiliação
  • Fenaux P; Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, 1 Avenue Claude Vellefaux, 75475, Paris, France. pierre.fenaux@aphp.fr.
  • Giagounidis A; Marien Hospital Düsseldorf, Düsseldorf, Germany.
  • Selleslag D; AZ St-Jan BruggeAV, Brugge, Belgium.
  • Beyne-Rauzy O; Purpan Pavillion de Medecines, Centre Hospitalier Universitaire, Toulouse, France.
  • Mittelman M; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Muus P; Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Nimer SD; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
  • Hellström-Lindberg E; Karolinska University Hospital, Stockholm, Sweden.
  • Powell BL; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
  • Guerci-Bresler A; CHU Brabois, University Center of Medicine, Vandoeuvre, France.
  • Sekeres MA; Cleveland Clinic, Cleveland, OH, USA.
  • Deeg HJ; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Del Cañizo C; Hospital Universitario de Salamanca, Salamanca, Spain.
  • Greenberg PL; Stanford Cancer Institute, Stanford, CA, USA.
  • Shammo JM; Rush University Medical Center, Chicago, IL, USA.
  • Skikne B; Celgene Corporation, Summit, NJ, USA.
  • Yu X; Celgene Corporation, Summit, NJ, USA.
  • List AF; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
J Hematol Oncol ; 10(1): 131, 2017 06 26.
Article em En | MEDLINE | ID: mdl-28651604

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Síndromes Mielodisplásicas / Fatores Imunológicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Síndromes Mielodisplásicas / Fatores Imunológicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article